Literature DB >> 29086115

Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Prasanna Santhanam1, Lilja B Solnes2, Steven P Rowe2.   

Abstract

An important aspect of differentiated thyroid cancer (DTC) management is disease localization by imaging. Functional imaging of thyroid cancer with iodinated radiotracers has been employed for metastatic disease detection for long. More recently, 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), a non-iodinated ubiquitous PET tracer, has been used to detect non-radioiodine (RAI) avid disease. Advances in molecular imaging have led to the development of newer tracers like 18F-TFB (18F-tetrafluoroborate) that are transported through the sodium-iodide symporter (NIS) as well as 68 Ga-DOTATATE that image the somatostatin receptors sub-type 2 expressed in medullary thyroid cancer and some DTC. In coming years, there will be focus on newer receptor targets like prostate-specific membrane antigen expression and endoradiotherapies and theranostics.

Entities:  

Keywords:  Differentiated Thyroid Cancer; Imaging; Radiotracers

Mesh：

Substances：

Year:  2017        PMID： 29086115     DOI： 10.1007/s12032-017-1051-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  64 in total

1.  THE COMBINED USE OF CALCITONIN DOUBLING TIME AND 18F-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF 18F-FDG PET/CT.

Authors:  Ji H Yang; Cléber P Camacho; Susan C Lindsey; Flavia O F Valente; Danielle M Andreoni; Lilian Y Yamaga; Jairo Wagner; Rosa Paula M Biscolla; Rui M B Maciel
Journal:  Endocr Pract       Date:  2017-06-14       Impact factor: 3.443

2.  Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.

Authors:  Susanne Lütje; Benedikt Gomez; Joseph Cohnen; Lale Umutlu; Martin Gotthardt; Thorsten D Poeppel; Andreas Bockisch; Sandra Rosenbaum-Krumme
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

3.  Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors:  M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

4.  Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer.

Authors:  Renaud Ciappuccini; Natacha Heutte; Géraldine Trzepla; Jean-Pierre Rame; Dominique Vaur; Nicolas Aide; Stéphane Bardet
Journal:  Eur J Endocrinol       Date:  2011-04-06       Impact factor: 6.664

5.  Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.

Authors:  Kathryn Tran; Sairah Khan; Mina Taghizadehasl; Fausto Palazzo; Andrea Frilling; Jeannie F Todd; Adil Al-Nahhas
Journal:  Hell J Nucl Med       Date:  2015-02-13       Impact factor: 1.102

6.  Fluorine-18 fluorodeoxyglucose avid thyroid incidentalomas on PET/CT scan in cancer patients: how sinister are they?

Authors:  Aamna Hassan; Saima Riaz; Waleed Zafar
Journal:  Nucl Med Commun       Date:  2016-10       Impact factor: 1.690

7.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.

Authors:  S I Sherman; E T Tielens; S Sostre; M D Wharam; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

8.  Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.

Authors:  Gowri L Kanthan; James Drummond; Geoff Paul Schembri; Michael A Izard; Edward Hsiao
Journal:  Clin Nucl Med       Date:  2016-04       Impact factor: 7.794

9.  Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?

Authors:  Pedro Wesley Souza Rosário; Alvaro Luís Barroso; Leonardo Lamego Rezende; Eduardo Lanza Padrão; Tales Alvarenga Fagundes; Gustavo Cancela Penna; Saulo Purisch
Journal:  Clin Nucl Med       Date:  2004-12       Impact factor: 7.794

10.  Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [(18)F]-tetrafluoroborate.

Authors:  J M Marti-Climent; M Collantes; M Jauregui-Osoro; G Quincoces; E Prieto; I Bilbao; M Ecay; J A Richter; I Peñuelas
Journal:  EJNMMI Res       Date:  2015-12-03       Impact factor: 3.138
View more
  3 in total

Review 1.  Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future.

Authors:  Laura Teodoriu; Letitia Leustean; Maria-Christina Ungureanu; Stefana Bilha; Irena Grierosu; Mioara Matei; Cristina Preda; Cipriana Stefanescu
Journal:  Diagnostics (Basel)       Date:  2022-04-10

2.  Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles.

Authors:  ZhongQian Hu; JiaLe Qin; TianKuan Li; JinHe Guo
Journal:  Int J Nanomedicine       Date:  2019-09-10

Review 3.  Thyroid cancer diagnosis in the era of precision imaging.

Authors:  Kimberley-Jane Bonjoc; Hannah Young; Susanne Warner; Thomas Gernon; Ellie Maghami; Ammar Chaudhry
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.